Home
Calithera Biosciences, Inc.

Calithera Biosciences, Inc. Market Share Analysis for May 2026

calithera is developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells.

Health > Biotechnology and Pharmaceuticals

Domaincalithera.com

Year Founded2010

Employees51 - 200

Annual Revenue$5M - $10M

Calithera Biosciences, Inc.

Calithera Biosciences, Inc. (including company regionals)

calithera.com

See more website traffic and engagement information

Calithera Biosciences, Inc. Revenue up to May 2026 is 5M - 10M

revenue generated by Calithera Biosciences, Inc. top domains

Calithera Biosciences, Inc. top domains revenue over 3 years

Revenue for Calithera Biosciences, Inc. top domains

calithera.com5M - 10M

See more with Sales Intelligence

Total visits to Calithera Biosciences, Inc.'s top domains

Understand Calithera Biosciences, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Calithera Biosciences, Inc.'s top domains

Analyze Calithera Biosciences, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Calithera Biosciences, Inc.'s top domains

See how Calithera Biosciences, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Calithera Biosciences, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Calithera Biosciences, Inc.

These are the website technologies, by industry, used by Calithera Biosciences, Inc. top domains

Widget (3)

Twemoji

Advertising (2)

DoubleClick

Mobile (2)

Meta Viewport

Content Management System (1)

WordPress

More Technologies

6

See all

News & Signals from Calithera Biosciences, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsDillon left Calithera Biosciences, Inc. as Senior Vice President of Commercial and Portfolio Strategy on Jan 1st '23.Dr. Dillon joins ALX Oncology from Calithera Biosciences, where she served as Senior Vice President of Commercial and Portfolio Strategy until 2023.

NewsTakeda Pharmaceuticals sold assets to Calithera Biosciences, Inc. in the amount of $45M on Jan 1st '21.In 2021, Calithera bought two Phase II cancer assets from Takeda in an attempt to bounce back, but it announced in November that data from the assets had been delayed.

NewsCalithera Biosciences, Inc. promotes Emil Kuriakose to chief medical officer.Finally, we announced the promotion of Emil Kuriakose to chief medical officer and the strengthening of our board of directors with the addition of Calithera’s former chief medical officer, Keith Orford.